Jefferies stays Buy on Erasca Inc (ERAS): ASCO'26 a potential inflection point with Ph1 monotx data presentation likely

Jefferies analyst Maury Raycroft reiterated a Buy rating and $21.00 price target on Erasca Inc (NASDAQ: ERAS)

The analyst commented, "We see ASCO’26 as a pot'l inflection point for ERAS, w/ ’0015’s initial ph.I monotx data likely presented there. That readout will test whether ERAS can match/beat RVMD on efficacy while differentiating on combinability (better rash/GI/stomatitis + linear PK). With early low-dose activity and preclin potency/PK edges, we believe even modest early separation should drive a (+)ve stock reaction as investors look through RVMD’s $30B+ takeout chatter."

For an analyst ratings summary and ratings history on Erasca Inc click here. For more ratings news on Erasca Inc click here.

Shares of Erasca Inc closed at $19.01 yesterday.

You May Also Be Interested In

• Erasca Inc (ERAS) PT Raised to $21 at Guggenheim
• TSS Inc (TSSI) PT Lowered to $13 at Needham
• StubHub Holdings (STUB) PT Lowered to $11 at Mizuho